Drugs / Army Liposomal Formulation
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04658667 | Feb 2022 → Jul 2024 | HIV infectious disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Army Liposomal Formulation | “ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.” NCT04658667 ↗ |
| Known as | ALFQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04658667 ↗ |
| Modality | Other / unclassified | “ALFQ (Army Liposomal Formulation) is a liposomal adjuvant” NCT04658667 ↗ |
| Route | Intramuscular | “Participants will receive 2 intramuscular (IM) injections into the quadriceps muscle at Day 0.” NCT04658667 ↗ |